Bone needle could save lives when veins collapse in blood disease emergencies

NCT ID NCT07239375

Knowledge-focused Sponsor: Shanxi Bethune Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at using a needle placed into the bone marrow (intraosseous infusion) to give fluids and medicines quickly to critically ill patients with blood diseases. Researchers will enroll 52 adults aged 18-65 to see how often the first attempt works and how safe it is. The goal is to find a reliable backup when standard IV access is not possible.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to: If successful, this could show that intraosseous infusion is a reliable emergency option for blood disease patients when standard IV access fails.
What could go wrong: This is a small, early observational study with only 52 participants. It is not designed to prove the technique works better than standard care, and complications like infection or fat embolism are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 52 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study Population: Fifty-two adult patients (18-65 years) with critical hematologic disorders and poor vascular access will be enrolled. All are at imminent risk of death and include: ① rapidly progressive, highly lethal hematologic malignancies; ② severe complications such as agranulocytosis, major bleeding, DIC, CNS involvement, or sepsis; ③ concomitant respiratory, cardiac, renal, or hepatic failure; ④ life-threatening toxicities from HSCT or novel immunotherapies (hyperacute GVHD, grade 3-4 CRS/ICANS, grade 3-4 ICI-related pneumonitis); ⑤ any other critically ill patient requiring 24-h organ-supportive care.

Ages: 18 to 65 years
Sex: Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Age: 18 to 65 years old. 2. Critically patients with hematologic diseases, including:① Highly suspected or diagnosed patients with rapidly progressing highly lethal hematological diseases;② Patients with hematological disorders complicated by severe complications, including agranulocytosis, thrombocytopenia, severe anemia, advanced tumors,septic shock, sepsis, DIC、 severe gastrointestinal bleeding, involvement of the central nervous system or intracranial hemorrhage, etc;③ Patients with hematological diseases combined with important organ dysfunction, including respiratory failure, heart failure, renal failure, liver failure, etc;④ Patients undergoing hematopoietic stem cell transplantation or those experiencing serious complications in new immunotherapy, such as hyperacute graft-versus-host disease (GVHD), grade 3-4 cytokine release syndrome (CRS) or immune effector cell associated neurotoxicity syndrome (ICANS), grade 3-4 immune checkpoint inhibitor associated interstitial lung disease, etc;⑤ Other critically patients who require life support and 24-hour monitoring. Exclusion Criteria: * 1\. Fracture at the intended puncture site (due to the risk of fluid extravasation into subcutaneous tissues). 2\. Extensive soft tissue injury at the intended puncture site, resulting in insufficient anatomical landmarks for safe puncture. 3\. Local infection in the intended puncture area. 4. History of major orthopedic surgery in the intended puncture region. 5. Presence of a local prosthetic implant. 6. A site previously used for intraosseous (IO) access within the last 24 hours (to avoid re-puncture).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematologic diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematologic disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intraosseous infusions

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

1 site. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Bone needle could save lives when veins collapse in blood disease emergencies

What the study statuses mean